MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. today announced that interim results from its ongoing long-term treatment (LTT) study demonstrate the RNS® System significantly reduces seizure frequency among adults who have a common form of epilepsy that is difficult to treat with medication. Results of the ongoing LTT study, which were recently published in Neurology, include data on 230 people with medically intractable partial onset epilepsy enrolled at 33 Comprehensive Epilepsy Centers in the United States. The median reduction in seizure frequency compared to patients’ pre-implant seizure frequency was 60 percent at the beginning of the third year post-implant and 66 percent at the beginning of the sixth year.
Help employers find you! Check out all the jobs and post your resume.
